27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
PTC Therapeutics Inc (NASDAQ:PTCT) says its APHENITY Phase 3 trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU) has achieved the primary endpoint.
PKU is a birth defect that causes an amino acid called phenylalanine to build up in the body.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The placebo-controlled portion of the study included 98 patients in the primary analysis population.
The mean percent Phe reduction in sepiapterin-treated patients was 63%.
The mean percent Phe reduction was 69% in the subset of classical PKU patients. Minimal reductions in Phe levels were observed in the placebo-treated patients resulting in a highly statistically significant sepiapterin treatment benefit (p<0.0001). < p>
Sepiapterin was generally well tolerated with no serious adverse events.
"The Phe reductions observed in the placebo-controlled portion of the study are consistent with, and, in some cases, exceed the magnitude of Phe reductions recorded in the open-label portion of the study," said Matthew Klein, Chief Executive Officer.
Price Action: PTCT shares are up 4.02% at $56.38 on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.